AstraZeneca inks U.S. co-commercialization deal for OIC med
Seeking Alpha - at Seeking Alpha - Thu Mar 19, 11:14AM CDT
AZN: 32.23 (-0.16), NKTR: 11.34 (+0.56)
FDA clears Daiichi-Sankyo anticoagulant
Seeking Alpha - at Seeking Alpha - Thu Jan 08, 6:55PM CST
PTLA: 43.31 (+0.76), PFE: 33.24 (+0.15), BMY: 61.44 (+0.93), JNJ: 95.37 (+0.29), ISIS: 43.24 (+0.86), MDCO: 34.88 (+0.07), BAX: 33.21 (-0.04), AZN: 32.23 (-0.16), MRK: 50.95 (-0.07), SCLN: 7.12 (+0.12), MSLI: 1.36 (unch)
ArQule prostate cancer drug candidate successful in Phase 2
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 9:19AM CST
ARQL: 2.04 (+0.05)
Ad Comm approaches for Daiichi Sankyo anticoagulant
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 12:49PM CDT
The Next Biotech Buyout Stock
Motley Fool Staff - Motley Fool - Fri Oct 10, 7:15AM CDT
Biotech stocks are notoriously volatile, making them best suited for only the most risk-tolerant investors. But for those willing to take the risk, biotech companies can often make a big splash; particularly when a bigger fish gobbles them up....
JNJ: 95.37 (+0.29), PTLA: 43.31 (+0.76), PFE: 33.24 (+0.15), BMY: 61.44 (+0.93), PRTA: 44.69 (+1.29), PBYI: 79.41 (+3.89)